The Medicines Company Announces Positive Topline Results for ORION-10 Phase 3 Study of Inclisiran in ASCVD Patients

Posted in Biotech by Medtech[y] Staff

September 25, 2019 • 2 min read

ORION-10 study met all primary and secondary endpoints, with durable and potent efficacy and excellent safety of inclisiran that were at least as favorable as observed in ORION-11. ORION-10 completion marks successful conclusion of pivotal Phase 3 LDL-C lowering studies of inclisiran. Detailed data from ORION-10 will be presented in a late-breaking science session at the American Heart Association Scientific Sessions in Philadelphia...